Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

WOW! Anyone else read this yet! Grrrrr! What’s true! Hehehe

$MorphoSys(MOR.US)$ MorphoSys Spokesperson Says "This Story Is Factually Wrong" In An Emailed Statement To Bloomberg News, In Response To STAT News' Adam Feuerstein Article Entitled, "Why Novartis Is Going To Walk Away From Its Acquisition"
Benzinga· 5 mins ago
Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com)
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.
MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.
This is all speculation on my part, but it's supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
3
Translate
Report
2940 Views
Comment
Sign in to post a comment
1754Followers
28Following
20KVisitors
Follow